Exelon Drug Identifiers
Links shared publicly online about this topic
Novartis files suit against Watson over generic Exelon
news-medical.net — “Watson Pharmaceuticals, Inc. today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market rivastigmine transdermal system patches, 4.6 mg/24 hr and 9.5 mg/24 hr.” View full resource at news-medical.net
Most Recently Shared on November 11, 2011 at 5:17 am By:
Parkinson's Disease: Novartis files suit against Watson over generic Exelon: Watson Pharmaceuticals, Inc. today ... http://t.co/ldd6pUdi
Novartis Europharm Ltd Withdraws its Applications for an Extension of the Indication for Exelon and Prometax (rivastigmine) - Drugs.com MedNews
drugs.com — “The European Medicines Agency has been formally notified by Novartis Europharm Ltd of its decision to withdraw its applications for an extension of the therapeu” View full resource at drugs.com
Most Recently Shared on March 16, 2012 at 2:02 pm By:
Drugs and Devices OW OW Health
Novartis Europharm Ltd Withdraws its Applications for an Extension of the Indication for Exelon and Promet... http://t.co/eDJZGt8w #drug
Novartis Europharm Ltd Withdraws its Applications for an Extension of the Indication for Exelon and Prometax (Rivastigmine) - Drugs.com MedNews
drugs.com — “From Targeted News Service (March 15, 2012) The European Union s Medicines Agency issued the following news release The European Medicines Agency has been forma” View full resource at drugs.com
Most Recently Shared on March 16, 2012 at 12:06 pm By:
Drugs and Devices OW OW Health
Novartis Europharm Ltd Withdraws its Applications for an Extension of the Indication for Exelon and Promet... http://t.co/LfAgJZpP #drug
Exelon | Drug safety information | Monitoring more than 280 patients | MediGuard
mediguard.org — “Exelon | Drug safety information | Monitoring more than 280 patients | MediGuard” View full resource at mediguard.org
Most Recently Shared on March 21, 2011 at 12:17 pm By:
MediGuard.org Health Organization
Over 110856888 #exelon users sharing experiences on MediGuard.org: http://tinyurl.com/6kp6x7c
Anti-Delirium Drug May Harm Critically Ill Patients - Drugs.com MedNews
drugs.com — “The anti-delirium drug rivastigmine (brand name Exelon) does not appear to control delirium in critically ill hospital patients, new Dutch research indicates. W” View full resource at drugs.com
Most Recently Shared on November 5, 2010 at 12:05 am By:
Drugs and Devices OW OW Health
Anti-Delirium Drug May Harm Critically Ill Patients: THURSDAY, Nov. 4 -- The anti-delirium drug rivastigmi... http://bit.ly/bvPjQH #drug
Anti-Delirium Drug May Harm Critically Ill Patients - Drugs.com MedNews
drugs.com — “The anti-delirium drug rivastigmine (brand name Exelon) does not appear to control delirium in critically ill hospital patients, new Dutch research indicates. W” View full resource at drugs.com
Most Recently Shared on November 5, 2010 at 3:17 am By:
Anti-Delirium Drug May Harm Critically Ill Patients - http://bit.ly/9lnPiq
$3m Raised For Alzheimer's Drug
medicalnewstoday.com — “The drug, ladostigil, is a molecule that combines components from the existing drugs Azilect and Exelon. Teva's Azilect, for the treatment of Parkinson's disease, was developed by Prof. Emeritus M” View full resource at medicalnewstoday.com
Most Recently Shared on November 17, 2011 at 10:05 am By:
MNT Alzheimer's News Health News
$3m Raised For Alzheimer's Drug http://t.co/eHGGFtXF #alzheimers
Anti-Delirium Drug May Harm Critically Ill Patients
health.yahoo.net — “THURSDAY, Nov. 4 (HealthDay News) -- The anti-delirium drug rivastigmine (brand name Exelon) does not appear to control delirium in critically ill hospital patients, new Dutch research indicates.” View full resource at health.yahoo.net
Most Recently Shared on November 5, 2010 at 11:39 am By:
Jennifer Ann Grisso Nurse and Active Health Library
Anti-Delirium Drug May Harm Critically Ill Patients: THURSDAY, Nov. 4 (HealthDay News) -- The anti-delirium drug... http://bit.ly/93LD10
Anti-Delirium Drug May Harm Critically Ill Patients
health.yahoo.net — “THURSDAY, Nov. 4 (HealthDay News) -- The anti-delirium drug rivastigmine (brand name Exelon) does not appear to control delirium in critically ill hospital patients, new Dutch research indicates.” View full resource at health.yahoo.net
Most Recently Shared on November 5, 2010 at 1:40 pm By:
Anti-Delirium Drug May Harm Critically Ill Patients http://bit.ly/bNZhOv
Anti-Delirium Drug May Harm Critically Ill Patients
health.yahoo.net — “THURSDAY, Nov. 4 (HealthDay News) -- The anti-delirium drug rivastigmine (brand name Exelon) does not appear to control delirium in critically ill hospital patients, new Dutch research indicates.” View full resource at health.yahoo.net
Most Recently Shared on November 5, 2010 at 11:29 am By:
Jane Anderson Healthy Eating Advisor
Anti-Delirium Drug May Harm Critically Ill Patients http://bit.ly/9fQFd5
Britain Gives Alzheimer's Drugs A Second Chance : Shots - Health Blog : NPR
npr.org — “In a reversal, the National Institute for Health and Clinical Excellence says Aricept, Razadyne and Exelon are worth the money when it comes to treating people with mild Alzheimer's disease. Four years ago the gatekeeper recommended against them.” View full resource at npr.org
Most Recently Shared on October 7, 2010 at 1:17 pm By:
Britain Gives Alzheimer's Drugs A Second Chance: In a reversal, the National Institute for Health and Clini... http://n.pr/bwRgEi from NPR
Lower Dementia Drug Dose Boosts Brain Function, Cuts Side Effects
sciencedaily.com — “Sometimes less is more: Lower doses of an Alzheimer's drug delivered via skin patches improve cognition with fewer serious side effects than higher doses, researchers have found in an updated review.” View full resource at sciencedaily.com
Most Recently Shared on April 29, 2009 at 2:42 pm By:
William Yates, M.D. Psychiatrist, Family Medicine Doctor, Physician, and Doctor
Exelon low-dose patch effective with less side effects in Alzheimer's. Cochrane Review http://bit.ly/FlxXS
Anti-Delirium Drug May Harm Critically Ill Patients --Doctors Lounge
doctorslounge.com — “Anti-Delirium Drug May Harm Critically Ill Patients --Doctors Lounge” View full resource at doctorslounge.com
Most Recently Shared on November 5, 2010 at 5:10 am By:
Drugs and Devices OW OW Health
Anti-Delirium Drug May Harm Critically Ill Patients: Exelon ineffective, raised risk of death in study http://bit.ly/9b3my3
Drug 'does not decrease delirium duration' | News | Nursing Times
nursingtimes.net — “The cholinesterase inhibiting drug rivastigmine (Exelon) does not decrease the duration of delirium in critically ill patients and could increase mortality, warn Dutch researchers.” View full resource at nursingtimes.net
Most Recently Shared on November 7, 2010 at 7:12 am By:
News: Drug 'does not decrease delirium duration' http://bit.ly/anEMJb
Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial
news-medical.net — “The drug, ladostigil, is a molecule that combines components from the existing drugs Azilect and Exelon. Teva's Azilect, for the treatment of Parkinson's disease, was developed by Prof. Emeritus Moussa Youdim of the Technion-Israel Institute of Technology. Azilect is the only anti-Parkinson's drug that has proven to have a disease-modifying effect. Novartis's Exelon was developed by Prof. Marta Weinstock-Rosin of Hebrew University to treat Alzheimer's disease.” View full resource at news-medical.net
Most Recently Shared on November 17, 2011 at 7:53 am By:
Alzheimers News: Avraham raises $3M to advance ladostigil Phase II Alzheimer's trial: The drug, ladostigil, is a... http://t.co/C8w04y75
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
News-Medical.Net
Stay up to date with the latest Parkinson's Disease news and research via News-Medical.Net
-
Drugs and Devices OW
Organizing drug and medical device resources shared by health experts, advocates, and organizations into WisdomCards.
-
Drugs and Devices OW
Organizing drug and medical device resources shared by health experts, advocates, and organizations into WisdomCards.
Advertisement
